Disease management strategies

September 2008
Pharmaceutical Representative;Sep2008, Vol. 38 Issue 9, p32
The article reports on the impact of disease management on the pharmaceutical industry in the U.S. It discusses the benefits of disease management to healthcare organizations and pharmaceutical companies. It identifies emerging strategies used by pharmaceutical companies in response to disease management. Also, it describes the new roles for healthcare representatives in the disease management environment.


Related Articles

  • How to start a diabetes management service. Shah, Monica // Drug Topics;9/12/2005, Vol. 149 Issue 17, p36 

    This article provides tips on how to start a diabetes screening and management service program. Before implementing any patient care service, the needs of the patients and other healthcare providers within the community should be assessed. The strengths and weaknesses of the pharmacists should...

  • Management of febrile neutropenia in the United Kingdom: time for a national trial? Innes, H.; Billingham, L.; Gaunt, C.; Steven, N.; Marshall, E. // British Journal of Cancer;12/12/2005, Vol. 93 Issue 12, p1324 

    Recent advances in febrile neutropenia (FN) have highlighted the value of risk stratification and the evolving role of oral antibiotics with early hospital discharge in low-risk patients. The aim of this study was to survey whether these advances have been translated into routine clinical...

  • The impact of bundled payments for diabetes care on curative health care costs - A 2-year follow-up study based on Dutch nationwide claim data. Mohnen, Sigrid M.; Baan, Caroline A.; Struijs, Jeroen N. // International Journal of Integrated Care (IJIC);Oct2013 Supplement, Vol. 13, p1 

    Introduction: In The Netherlands, disease management programs (DMPs) based on Bundled Payment (BP) for chronic diseases were initiated to, inter alia, slow down the costs growth. To date, it is unknown whether the BP model for diabetes care increased or reduced the cost growth in comparison to...

  • New math provides an epiphany for measuring ROI. Lewis, Al // Managed Healthcare Executive;Apr2007, Vol. 17 Issue 4, p39 

    The article cites a paper that discusses the return on investment (ROI) of disease management (DM). This study proves that planwide rates for heart attacks, asthma attacks and other disease-specific avoidable events would have to fall by 20 percent or more just to break even on a DM program....

  • DM programs require deep thinking. Walker, Tracey // Managed Healthcare Executive;Apr2007, Vol. 17 Issue 4, p48 

    The article focuses on the need to develop more creative disease management programs for such diseases as diabetes, asthma, cardiovascular disorders and chronic obstructive pulmonary disease. Employers need to know how to measure the success of disease management programs on return to work. For...

  • Return on Investment in Disease Management: A Review. Goetzel, Ron Z.; Ozminkowski, Ronald J.; Villagra, Victor G.; Duffy, Jennifer // Health Care Financing Review;Summer2005, Vol. 26 Issue 4, p1 

    The results of 44 studies investigating financial impact and return on investment (ROI) from disease management (DM) programs for asthma, congestive heart failure (CHF), diabetes, depression, and multiple illnesses were examined. A positive ROI was found for programs directed at CHF and multiple...

  • Changing the Treatment Paradigm: Moving to Multimodal and Integrated Osteoarthritis Disease Management. Brander, Victoria // Journal of Family Practice;Nov2011 Supplement 2, pS41 

    The article discusses the changes of treatment and management of osteoarthritis (OA) disease. It notes the importance of an improved treatment and management of OA follwing the increasing number of patients with such disease. It examines how OA care delivery using disease-management strategies...

  • Milliman offers guidance on disease management.  // Modern Healthcare;8/16/2004, Vol. 34 Issue 33, p33 

    Presents information on a study which examined regression to the mean and selection bias, elements that often confound cost-benefit analyses of disease management. Three disease states that are typically addressed by disease management programs; Effects of selection bias on the utilization and...

  • Disease management--principles and perspectives:Lessons from congestive heart failure in the European Union. Labiris, Georgios // International Journal of Medical Marketing;Apr2004, Vol. 4 Issue 2, p168 

    Presents the principles and perspectives of Disease Management Programmes and lessons from the congestive heart failure in the European Union. Definition of and approach to disease management programmes; Experience of the Florida Legislature in the congestive heart failure (CHF) disease...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics